InvestorsHub Logo
Followers 368
Posts 5763
Boards Moderated 0
Alias Born 07/18/2009

Re: None

Friday, 10/25/2019 8:25:43 PM

Friday, October 25, 2019 8:25:43 PM

Post# of 1271
On October 21, 2019, the company sold one (1) million shares of its preferred shares (one preferred share is convertible 1,000 share of common stocks) of the company for aggregate purchase price of $55,000.00 to Cannabinoid Biosciences, Inc., a California corporation.

The issuance of the preferred shares to Cannabinoid Biosciences, Inc.; therefore, give to Cannabinoid Biosciences, Inc, the controlling vote to control and dominate the affairs of the company going forward.

As a result of the foregoing Cannabinoid Biosciences, Inc., who converted 70,000 of the preferred shares now control approximately 70.00% of the Company's current outstanding shares of common stock (on a fully diluted basis).

As a result of the Securities Sales Agreement, all the former officers of company resigned their appointments. The Company has appointed Mr. Frank I Igwealor as the Company's Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors effective October 23, 2019